The estimated Net Worth of Michael Berelowitz is at least $449 Tisíc dollars as of 9 March 2018. Michael Berelowitz owns over 7,500 units of Recro Pharma Inc stock worth over $15,675 and over the last 11 years he sold REPH stock worth over $17,918. In addition, he makes $415,003 as Independent Director at Recro Pharma Inc.
Sign up
Michael Berelowitz REPH stock SEC Form 4 insiders trading
Michael has made over 4 trades of the Recro Pharma Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 7,500 units of REPH stock worth $18,525 on 9 March 2018.
The largest trade he's ever made was exercising 9,434 units of Recro Pharma Inc stock on 31 March 2014 worth over $48,774. On average, Michael trades about 1,052 units every 80 days since 2014. As of 9 March 2018 he still owns at least 7,500 units of Recro Pharma Inc stock.
You can see the complete history of Michael Berelowitz stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Berelowitz biography
Dr. Michael Berelowitz M.D. serves as Independent Director of the Company. Dr. Berelowitz has served as our biopharmaceutical consultant. From 2009 to 2011, Dr. Berelowitz was Senior Vice President and Head of Clinical Development and Medical Affairs in the Specialty Care Business Unit at Pfizer, Inc., or Pfizer, a pharmaceutical company. From 1996 to 2009, he held various other roles at Pfizer, Inc., beginning as a Medical Director in the Diabetes Clinical Research team and then assuming positions of increasing responsibility. Prior to that, Dr. Berelowitz spent a number of years in academia. Dr. Berelowitz previously served on the board of directors of Oramed Pharmaceuticals Inc. from June 2010 to August 2016, Kamada Ltd. and Cellect Biotherapeutics Ltd. Among his public activities, Dr. Berelowitz has served on the board of directors of the American Diabetes Association and the Clinical Initiatives Committee of the Endocrine Society, and has chaired the Task Force on Research of the New York State Council on Diabetes. He has also served on several editorial boards, including the Journal of Clinical Endocrinology and Metabolism and Endocrinology, Reviews in Endocrine and Metabolic Disorders and Clinical Diabetes. Dr. Berelowitz has authored and co-authored more than 100 peer-reviewed journal articles and book chapters in the areas of pituitary growth hormone regulation, diabetes and metabolic disorders.
What is the salary of Michael Berelowitz?
As the Independent Director of Recro Pharma Inc, the total compensation of Michael Berelowitz at Recro Pharma Inc is $415,003. There are 5 executives at Recro Pharma Inc getting paid more, with Geraldine Henwood having the highest compensation of $4,622,980.
How old is Michael Berelowitz?
Michael Berelowitz is 75, he's been the Independent Director of Recro Pharma Inc since 2014. There are 1 older and 8 younger executives at Recro Pharma Inc. The oldest executive at Recro Pharma Inc is Winston Churchill, 79, who is the Independent Director.
What's Michael Berelowitz's mailing address?
Michael's mailing address filed with the SEC is C/O RECRO PHARMA, INC., 490 LAPP ROAD, MALVERN, PA, 19355.
Insiders trading at Recro Pharma Inc
Over the last 11 years, insiders at Recro Pharma Inc have traded over $25,533,136 worth of Recro Pharma Inc stock and bought 3,055,820 units worth $22,429,197 . The most active insiders traders include Healthcare Master Fund Ltd ..., Investment Company, Inc. Awm a James E Deerfield Mgmt L.P..... On average, Recro Pharma Inc executives and independent directors trade stock every 31 days with the average trade being worth of $151,953. The most recent stock trade was executed by J David Jr Enloe on 15 March 2022, trading 512 units of REPH stock currently worth $1,004.
What does Recro Pharma Inc do?
Recro Pharma Inc. is a contract development and manufacturing organization (CDMO) with capabilities from early feasibility to commercial manufacturing. With an expertise in solving complex manufacturing problems, Recro is a leading CDMO providing oral solid dosage form development, end-to-end regulatory support, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market.
What does Recro Pharma Inc's logo look like?
Complete history of Michael Berelowitz stock trades at Oramed Pharmaceuticals, Inc a Recro Pharma Inc
Recro Pharma Inc executives and stock owners
Recro Pharma Inc executives and other stock owners filed with the SEC include:
-
Geraldine Henwood,
President, Chief Executive Officer, Director -
Ryan Lake,
Chief Financial Officer -
William Ashton,
Independent Director -
Wayne Weisman,
Independent Chairman of the Board -
Winston Churchill,
Independent Director -
Michael Berelowitz,
Independent Director -
Ryan D. Lake,
Chief Financial Officer -
Bryan Reasons,
Independent Director -
J. David Enloe Jr.,
Pres, CEO & Director -
Argot Partners,
IR Contact Officer -
Tim Bourque,
VP of Operations & Site Head of San Diego -
David Smithwick B.S.,
VP of Operations & Site Head of Gainesville -
Richard Sidwell Ph.D.,
VP & Chief Scientific Officer -
Marshall Rizzo M.B.A.,
Sr. VP & GM -
Randall J. Mack,
Sr. VP of Devel. -
Erica Raether M.A.,
VP of People, Culture & ESG -
William Hirschman,
VP of Sales & Marketing -
Matthew McKendry,
Director of Accounting -
Laura L. Parks,
Director -
Karen Flynn,
Director -
Vitalife Partners Ii Lp Scp,
10% owner -
Donna Nichols,
CAO/Controller -
Stewart Mc Callum,
Chief Medical Officer -
Randall Mack,
Senior VP, Development -
Fred Graff,
Chief Commercial Officer -
Capital Management, Llc Sto...,
10% owner -
James E Deerfield Mgmt L.P....,
-
Vitalife Partners (Israel) ...,
10% owner -
Alfred Altomari,
Director -
Healthcare Master Fund Ltd ...,
-
Diane Myers,
Senior VP-Reg./Quality -
Jyrki Mattila,
Executive VP, Business Dev. -
Michael Celano,
Chief Financial Officer -
Arnaud Ajdler,
Director -
Abraham Ludomirski,
Director -
Charles Garner,
CFO and Chief Business Officer -
J David Jr Enloe,
Chief Executive Officer -
James Charles Miller,
Director -
Investment Company, Inc. Awm,
10% owner